phrykt

Myriad Genetics Inc (MYGN): who owns it and who trades it

As of Nov 16, 2026, MYGN insiders reported 1 open-market sale worth $66.9K and 5 purchases worth $722K in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Rashmi Kumar (Director), with $66.9K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Myriad Genetics

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MYGN

195 funds and institutions reported MYGN shares worth $524M at the end of Q2 2026, about 97% of the company. The largest holder is BlackRock, Inc. with 11.5%.

Funds and institutions (13F) 97%Everyone else 3%

10 largest owners, by share of the company

BlackRock, Inc.11.5%
Millennium Management LLC7.0%
Vestal Point Capital, LP6.1%
State Street Corp5.3%
D. E. Shaw & Co., Inc.4.9%
Vanguard Capital Management LLC4.3%
Acadian Asset Management LLC3.3%
Vanguard Portfolio Management LLC3.3%
AQR Capital Management LLC2.9%
Morgan Stanley2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.10.89M11.53%$62.2M+23%
Millennium Management LLC6.62M7.01%$37.8M-1%
Vestal Point Capital, LP5.74M6.07%$32.7M+248%
State Street Corp4.99M5.28%$28.5M+13%
D. E. Shaw & Co., Inc.4.58M4.85%$26.2M+2%
Vanguard Capital Management LLC4.08M4.32%$23.3M+4%
Acadian Asset Management LLC3.13M3.31%$17.8M+35%
Vanguard Portfolio Management LLC3.08M3.26%$17.6M+19%
AQR Capital Management LLC2.77M2.93%$15.8M+45%
Morgan Stanley2.48M2.63%$14.2M-22%
Geode Capital Management, LLC2.42M2.56%$13.8M+4%
Assenagon Asset Management S.A.2.06M2.18%$11.8M+43%
Goldman Sachs Group Inc2.06M2.18%$11.7M-13%
Jacobs Levy Equity Management, Inc1.89M2.00%$10.8M-9%
Charles Schwab Investment Management Inc1.74M1.84%$9.9M-3%
Sixth Street Partners Management Company, L.P.1.74M1.84%$9.9M–
Qube Research & Technologies Ltd1.67M1.76%$9.5M-1%
Federated Hermes, Inc.1.57M1.66%$9M-21%
Two Sigma Investments, LP1.56M1.65%$8.9M+21%
Nuveen, LLC1.55M1.64%$8.8M+68%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MYGN insiders reported $722K of open-market purchases and $66.9K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$722K
5 trades, 3 people
Sales, 12 months
$66.9K
1 trades, 1 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Jun 8, 2026
Filed Jun 9, 2026

Purchases and sales by month

$495K$495KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 8, 2026Rashmi KumarDirectorSale plan15,000$4.46$66.9KForm 4
May 14, 2026Paul BisaroDirectorPurchase7,500$3.69$27.7KForm 4
Mar 9, 2026Samraat S. RahaCEOPurchase40,000$5.00$200KForm 4
Feb 27, 2026S. Louise PhanstielDirectorPurchase48,000$4.66$224KForm 4
Feb 26, 2026S. Louise PhanstielDirectorPurchase50,407$4.80$242KForm 4
Feb 25, 2026S. Louise PhanstielDirectorPurchase6,100$4.74$28.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
S. Louise PhanstielDirector$495K–Feb 27, 2026
Samraat S. RahaPresident and CEO, Director$200K–Mar 9, 2026
Rashmi KumarDirector–$66.9KJun 8, 2026
Paul BisaroDirector$27.7K–May 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MYGN short interest

Moderate short interest. 8.8% of MYGN shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 1%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 8.44M MYGN shares were sold short, 8.8% of the shares outstanding, down 9.0% from the report before. At the average daily volume of 4.24M shares, buying them all back would take about 2.0 trading days (days to cover).

Shares short, % of all shares

8.79%May 15Oct 3010.0%

Days to cover

2.0May 15Oct 308.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20268.44M8.79%-9%4.24M2.0
Oct 15, 20269.27M9.69%+8%1.74M5.3
Sep 30, 20268.55M8.93%-9%2.01M4.2
Sep 15, 20269.35M9.77%+19%2.19M4.3
Aug 31, 20267.84M8.20%+2%1.57M5.0
Aug 14, 20267.68M8.03%-10%2.59M3.0
Jul 31, 20268.50M8.88%+6%2.17M3.9
Jul 15, 20268.01M8.48%-6%1.09M7.3
Jun 30, 20268.56M9.07%-1%1.96M4.4
Jun 15, 20268.65M9.16%+1%1.51M5.7
May 29, 20268.55M9.06%+3%2.02M4.2
May 15, 20268.33M8.82%+6%2.19M3.8

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Myriad Genetics company events

Myriad Genetics filed 12 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026LeadershipThe Compensation and Human Capital Committee of the Board of Directors of Myriad Genetics, Inc. approved one-time equity awards in the form of stock options for certain executive officers of the Company, including its named executive officers, in order to promote the retention and continuity of the… Filing
  2. Nov 5, 2026AnnouncementMyriad Genetics, Inc. detected unauthorized access within its information technology network environment. Filing
  3. Nov 4, 2026ResultsReleased financial results. Filing
  4. Oct 20, 2026AgreementMyriad Genetics, Inc., a Delaware corporation, and Laboratory Corporation of America, a Delaware corporation, entered into an Asset Purchase Agreement. Filing
  5. Oct 9, 2026LeadershipMyriad Genetics, Inc. entered into a Separation Agreement and Release of Claims with Brian Donnelly, the Company’s former Chief Commercial Officer. Filing
  6. Sep 16, 2026LeadershipMyriad Genetics, Inc. announced that, effective September 16, 2026, Brian Donnelly no longer serves as Chief Commercial Officer of the Company. Filing
  7. Jul 30, 2026ResultsReleased financial results. Filing
  8. Jun 23, 2026LeadershipDaniel M. Skovronsky M.D., Ph.D., a member of the Board of Directors of Myriad Genetics, Inc. notified the Company that he is resigning as a director, effective immediately. Filing
  9. Jun 4, 2026LeadershipAs reported below in Item 5.07, Myriad Genetics, Inc. held its 2026 Annual Meeting of Stockholders, at which the Company's stockholders approved an amendment to the Company's Amended and Restated 2012 Employee Stock Purchase Plan, to increase the number of shares authorized for issuance under the… Filing
  10. May 5, 2026ResultsReleased financial results. Filing
  11. Feb 23, 2026ResultsReleased financial results. Filing
  12. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Myriad Genetics financials

Famous investors that hold MYGN

5 of the 50 well-known investors we track reported holding MYGN in their latest 13F filing. The largest position is Israel Englander's, worth $31.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20267.23M$31.2M0.0%+9%
Steve Cohen · Point72 Asset ManagementQ3 20263.23M$13.9M0.0%+1252%
Ken Griffin · Citadel AdvisorsQ3 20262.15M$9.3M0.0%+40%
Jim Simons · Renaissance TechnologiesQ3 2026243,645$1.1M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202645,520$196K0.0%+2%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named MYGN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Vestal Point Capital, LP13G/A0.0%
Nov 16, 2026Vestal Point Capital, LP13G/A0.0%
Oct 27, 2026BlackRock Portfolio Management LLC13G/A8.6%
Oct 27, 2026BlackRock Portfolio Management LLC13G/A8.6%

Questions about Myriad Genetics Inc (MYGN) stock

Who owns the most MYGN stock?

The largest reported owner of Myriad Genetics Inc (MYGN) is BlackRock, Inc., with 11.5% of the company. In total, 195 funds and institutions reported holding MYGN at the end of Q2 2026, together about 97% of the shares. See the largest owners.

Are MYGN insiders buying or selling?

In the last 12 months, MYGN insiders reported 5 open-market purchases worth $722K and 1 sale worth $66.9K. The latest trade was on Jun 8, 2026. See every trade.

What is the short interest in MYGN?

As of Oct 30, 2026, 8.44M MYGN shares were sold short, 8.8% of the shares outstanding, down 9.0% from the report before. At the average daily volume of 4.24M shares, buying them all back would take about 2.0 trading days (days to cover). See the history.

Which famous investors hold MYGN?

5 of the 50 well-known investors we track reported MYGN in their latest 13F filing, including Israel Englander, Steve Cohen, Ken Griffin. The largest position is worth $31.2M. See all holders.

Executive pay

Myriad Genetics's chief executive was paid a total of $13.6M for the year ended Dec 31, 2024, up 13% from $12.1M the year before. In the last 12 months, Myriad Genetics's executives and directors bought $722K of stock on the open market and sold $66.9K.

Chief executive, total pay$13.6MYear ended Dec 31, 2024. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$7.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.